Cancer Cell Biology

You have full text access to this OnlineOpen article

FOXA1: Growth inhibitor and a favorable prognostic factor in human breast cancer

  1. Ido Wolf1,†,*,
  2. Shikha Bose2,
  3. Elizabeth A. Williamson1,
  4. Carl W. Miller1,
  5. Beth Y. Karlan3,
  6. H. Phillip Koeffler1

Article first published online: 12 DEC 2006

DOI: 10.1002/ijc.22389

Issue

International Journal of Cancer

International Journal of Cancer

Volume 120, Issue 5, pages 1013–1022, 1 March 2007

Additional Information

How to Cite

Wolf, I., Bose, S., Williamson, E. A., Miller, C. W., Karlan, B. Y. and Koeffler, H. P. (2007), FOXA1: Growth inhibitor and a favorable prognostic factor in human breast cancer. Int. J. Cancer, 120: 1013–1022. doi: 10.1002/ijc.22389

Author Information

  1. 1

    Division of Hematology/Oncology, Cedars-Sinai Medical Center, UCLA School of Medicine, Los Angeles, CA

  2. 2

    Department of Anatomic Pathology, Cedars-Sinai Medical Center, UCLA School of Medicine, Los Angeles, CA

  3. 3

    Women's Cancer Research Institute, Cedars-Sinai Medical Center, UCLA School of Medicine, Los Angeles, CA

  1. †

    Fax: +972-3-530.

*Institute of Oncology, Sheba Medical Center, Tel-Hashomer, 52621 Israel

Publication History

  1. Issue published online: 19 JAN 2007
  2. Article first published online: 12 DEC 2006
  3. Manuscript Accepted: 6 SEP 2006
  4. Manuscript Received: 11 MAY 2006

Funded by

  • Inger Fund
  • Alec Borden Trust
  • Rountree Trust
  • Mary Barry Foundation
  • Women's Cancer Research Institute
  • Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center
  • Mary Barry Medical Bridges Foundation

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (509K)

References

  • 1
    Carlsson P, Mahlapuu M. Forkhead transcription factors: key players in development and metabolism. Dev Biol 2002; 250: 1–23.
  • 2
    Kaestner KH. The hepatocyte nuclear factor 3 (HNF3 or FOXA) family in metabolism. Trends Endocrinol Metab 2000; 11: 281–5.
  • 3
    Cirillo LA, Lin FR, Cuesta I, Friedman D, Jarnik M, Zaret KS. Opening of compacted chromatin by early developmental transcription factors HNF3 (FoxA) and GATA-4. Mol Cell 2002; 9: 279–89.
  • 4
    Pani L, Overdier DG, Porcella A, Qian X, Lai E, Costa RH. Hepatocyte nuclear factor 3 β contains two transcriptional activation domains, one of which is novel and conserved with the Drosophila fork head protein. Mol Cell Biol 1992; 12: 3723–32.
  • 5
    Qian X, Costa RH. Analysis of hepatocyte nuclear factor-3 β protein domains required for transcriptional activation and nuclear targeting. Nucleic Acids Res 1995; 23: 1184–91.
  • 6
    Tomaru Y, Kondo S, Suzuki M, Hayashizaki Y. A comprehensive search for HNF-3α-regulated genes in mouse hepatoma cells by 60K cDNA microarray and chromatin immunoprecipitation/PCR analysis. Biochem Biophys Res Commun 2003; 310: 667–74.
  • 7
    Kaestner KH, Katz J, Liu Y, Drucker DJ, Schutz G. Inactivation of the winged helix transcription factor HNF3α affects glucose homeostasis and islet glucagon gene expression in vivo. Genes Dev 1999; 13: 495–504.
  • 8
    Shih DQ, Navas MA, Kuwajima S, Duncan SA, Stoffel M. Impaired glucose homeostasis and neonatal mortality in hepatocyte nuclear factor 3α-deficient mice. Proc Natl Acad Sci USA 1999; 96: 10152–7.
  • 9
    Lin L, Miller CT, Contreras JI, Prescott MS, Dagenais SL, Wu R, Yee J, Orringer MB, Misek DE, Hanash SM, Glover TW, Beer DG. The hepatocyte nuclear factor 3 α gene, HNF3α (FOXA1), on chromosome band 14q13 is amplified and overexpressed in esophageal and lung adenocarcinomas. Cancer Res 2002; 62: 5273–9.
  • 10
    Gao N, Zhang J, Rao MA, Case TC, Mirosevich J, Wang Y, Jin R, Gupta A, Rennie PS, Matusik RJ. The role of hepatocyte nuclear factor-3 α (Forkhead Box A1) and androgen receptor in transcriptional regulation of prostatic genes. Mol Endocrinol 2003; 17: 1484–507.
  • 11
    Yu X, Gupta A, Wang Y. Foxa1 and foxa2 interact with the androgen receptor to regulate prostate and epididymal genes differentially. Ann N Y Acad Sci 2005; 1061: 77–93.
    Direct Link:
  • 12
    Perou CM, Jeffrey SS, van de Rijn M, Rees CA, Eisen MB, Ross DT, Pergamenschikov A, Williams CF, Zhu SX, Lee JC, Lashkari D, Shalon D, et al. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci USA 1999; 96: 9212–7.
  • 13
    van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530–6.
  • 14
    Doane AS, Danso M, Lal P, Donaton M, Zhang L, Hudis C, Gerald WL. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 2006; 25: 3994–4008.
  • 15
    Oh DS, Troester MA, Usary J, Hu Z, He X, Fan C, Wu J, Carey LA, Perou CM. Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. J Clin Oncol 2006; 24: 1656–64.
  • 16
    Frasor J, Danes JM, Komm B, Chang KC, Lyttle CR, Katzenellenbogen BS. Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 2003; 144: 4562–74.
  • 17
    Williamson EA, Wolf I, O'Kelly J, Bose S, Tanosaki S, Koeffler HP. BRCA1 and FOXA1 proteins coregulate the expression of the cell cycle-dependent kinase inhibitor p27(Kip1). Oncogene 2006; 25: 1391–9.
  • 18
    Laganiere J, Deblois G, Lefebvre C, Bataille AR, Robert F, Giguere V. Location analysis of estrogen receptor α target promoters reveals that FOXA1 defines a domain of the estrogen response. Proc Natl Acad Sci USA 2005; 102: 11651–6.
  • 19
    Carroll JS, Liu XS, Brodsky AS, Li W, Meyer CA, Szary AJ, Eeckhoute J, Shao W, Hestermann EV, Geistlinger TR, Fox EA, Silver PA, et al. Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell 2005; 122: 33–43.
  • 20
    Lacroix M, Leclercq G. Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res Treat 2004; 83: 249–89.
  • 21
    Fan S, Wang J, Yuan R, Ma Y, Meng Q, Erdos MR, Pestell RG, Yuan F, Auborn KJ, Goldberg ID, Rosen EM. BRCA1 inhibition of estrogen receptor signaling in transfected cells. Science 1999; 284: 1354–6.
  • 22
    Tong D, Schuster E, Seifert M, Czerwenka K, Leodolte S, Zeillinger R. Expression of estrogen receptor β isoforms in human breast cancer tissues and cell lines. Breast Cancer Res Treat 2002; 71: 249–55.
  • 23
    Rochefort H, Glondu M, Sahla ME, Platet N, Garcia M. How to target estrogen receptor-negative breast cancer? Endocr Relat Cancer 2003; 10: 261–6.
  • 24
    Chiarle R, Pagano M, Inghirami G. The cyclin dependent kinase inhibitor p27 and its prognostic role in breast cancer. Breast Cancer Res 2001; 3: 91–4.
  • 25
    Sgambato A, Zhang YJ, Arber N, Hibshoosh H, Doki Y, Ciaparrone M, Santella RM, Cittadini A, Weinstein IB. Deregulated expression of p27(Kip1) in human breast cancers. Clin Cancer Res 1997; 3: 1879–87.
  • 26
    Fredersdorf S, Burns J, Milne AM, Packham G, Fallis L, Gillett CE, Royds JA, Peston D, Hall PA, Hanby AM, Barnes DM, Shousha S, et al. High level expression of p27(kip1) and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27(kip1) and degree of malignancy in human breast and colorectal cancers. Proc Natl Acad Sci USA 1997; 94: 6380–5.
  • 27
    Menjo M, Kaneko Y, Ogata E, Ikeda K, Nakanishi M. Critical role for p27Kip1 in cell cycle arrest after androgen depletion in mouse mammary carcinoma cells (SC-3). Oncogene 1998; 17: 2619–27.
  • 28
    Shimizu S, Miyamoto Y, Hayashi M. Cell-type dependency of two Foxa/HNF3 sites in the regulation of vitronectin promoter activity. Biochim Biophys Acta 2002; 1574: 337–44.
  • 29
    Bailly A, Spath G, Bender V, Weiss MC. Phenotypic effects of the forced expression of HNF4 and HNF1α are conditioned by properties of the recipient cell. J Cell Sci 1998; 111: 2411–21.
  • 30
    Zhao HH, Herrera RE, Coronado-Heinsohn E, Yang MC, Ludes-Meyers JH, Seybold-Tilson KJ, Nawaz Z, Yee D, Barr FG, Diab SG, Brown PH, Fuqua SA, et al. Forkhead homologue in rhabdomyosarcoma functions as a bifunctional nuclear receptor-interacting protein with both coactivator and corepressor functions. J Biol Chem 2001; 276: 27907–12.
  • 31
    Schuur ER, Loktev AV, Sharma M, Sun Z, Roth RA, Weigel RJ. Ligand-dependent interaction of estrogen receptor-α with members of the forkhead transcription factor family. J Biol Chem 2001; 276: 33554–60.
  • 32
    Lacroix M, Leclercq G. About GATA3, HNF3A and XBP1, three genes coexpressed with the oestrogen receptor-α gene (ESR1) in breast cancer. Mol Cell Endocrinol 2004; 219: 1–7.
  • 33
    Unterman TG, Fareeduddin A, Harris MA, Goswami RG, Porcella A, Costa RH, Lacson RG. Hepatocyte nuclear factor-3 (HNF-3) binds to the insulin response sequence in the IGF binding protein-1 (IGFBP-1) promoter and enhances promoter function. Biochem Biophys Res Commun 1994; 205: 1496.
  • 34
    Jacob A, Budhiraja S, Reichel RR. The HNF-3α transcription factor is a primary target for retinoic acid action. Exp Cell Res 1999; 250: 1–9.
  • 35
    Yang Q, Sakurai T, Kakudo K. Retinoid, retinoic acid receptor β and breast cancer. Breast Cancer Res Treat 2002; 76: 167–73.
  • 36
    Clark KL, Halay ED, Lai E, Burley SK. Cocrystal structure of the HNF-3/fork head DNA-recognition motif resembles histone H5. Nature 1993; 364: 412–20.
  • 37
    Abba MC, Drake JA, Hawkins KA, Hu Y, Sun H, Notcovich C, Gaddis S, Sahin A, Baggerly K, Aldaz CM. Transcriptomic changes in human breast cancer progression as determined by serial analysis of gene expression. Breast Cancer Res 2004; 6: R499–R513.
View Full Article (HTML) Get PDF (509K)